APRILBIO CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20,800 KRW | -3.26% |
|
+18.65% | +23.44% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 363,525 | 451,810 | 451,810 | - |
| Enterprise Value (EV) 2 | 363.5 | 410.2 | 387.8 | 382.8 |
| P/E ratio | - | -31.4 x | 53.5 x | -176 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 1,818 x | - | 16.7 x | 37.7 x |
| EV / Revenue | 1,818 x | - | 14.4 x | 31.9 x |
| EV / EBITDA | - | -32.3 x | 55.4 x | -153 x |
| EV / FCF | - | -39.7 x | -64.6 x | -191 x |
| FCF Yield | - | -2.52% | -1.55% | -0.52% |
| Price to Book | - | 7.77 x | 6.83 x | 7.33 x |
| Nbr of stocks (in thousands) | 21,574 | 21,722 | 21,722 | - |
| Reference price 3 | 16,850 | 20,800 | 20,800 | 20,800 |
| Announcement Date | 4/27/23 | 3/12/24 | - | - |
1KRW in Million2KRW in Billions3KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | 0.2 | - | 27 | 12 |
| EBITDA 1 | - | -12.71 | 7 | -2.5 |
| EBIT 1 | - | -13.39 | 7 | -3 |
| Operating Margin | - | - | 25.93% | -25% |
| Earnings before Tax (EBT) 1 | - | -14.13 | 9 | -2.5 |
| Net income 1 | -8.959 | -14.13 | 8 | -2.5 |
| Net margin | -4,479.64% | - | 29.63% | -20.83% |
| EPS 2 | - | -662.0 | 389.0 | -118.0 |
| Free Cash Flow 3 | - | -10,334 | -6,000 | -2,000 |
| FCF margin | - | - | -22,222.22% | -16,666.67% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 4/27/23 | 3/12/24 | - | - |
1KRW in Billions2KRW3KRW in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | - | 41.6 | 64 | 69 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 2 | - | -10,334 | -6,000 | -2,000 |
| ROE (net income / shareholders' equity) | - | -22.3% | 13.6% | -4.9% |
| ROA (Net income/ Total Assets) | - | -18.7% | 9.9% | -3.95% |
| Assets 1 | - | 75.4 | 80.81 | 63.29 |
| Book Value Per Share 3 | - | 2,677 | 3,047 | 2,839 |
| Cash Flow per Share 3 | - | -471.0 | -442.0 | -401.0 |
| Capex 1 | - | 0.27 | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 4/27/23 | 3/12/24 | - | - |
1KRW in Billions2KRW in Million3KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
20,800
KRW
Average target price
28,500
KRW
Spread / Average Target
+37.02%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +23.44% | 341M | |
| +20.12% | 127B | |
| +25.25% | 117B | |
| +25.56% | 27.77B | |
| -19.51% | 20.44B | |
| -14.36% | 16.62B | |
| -15.63% | 15.92B | |
| -46.67% | 14.94B | |
| +11.89% | 14.74B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- A397030 Stock
- Financials AprilBio Co.,Ltd.
